vida: extract claims from 2026-04-22-npr-glp1-coverage-decline-insurance-slipping-2026

- Source: inbox/queue/2026-04-22-npr-glp1-coverage-decline-insurance-slipping-2026.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-employer-coverage-declining-despite-utilization-growth-creating-access-gap.md

@@ -46,3 +46,10 @@ The FDA's April 2026 clarification targeted combination formulations (semaglutid
 **Source:** KFF 2025, Mercer 2026, DistilINFO via NPR
 
 Reconciliation of apparent contradiction: KFF shows 49% large employer coverage (up from 44%), Mercer shows 90% large employer retention, yet DistilINFO confirms 22% decline in total covered lives. The resolution: large employers (500+) are stable/expanding while smaller employers, health systems, state plans, and regional payers withdraw coverage. The net effect is population-level coverage decline despite large-employer stability. This confirms the bifurcation pattern where employer size predicts coverage persistence.
+
+
+## Supporting Evidence
+
+**Source:** NPR April 22, 2026; Mercer 2026
+
+NPR provides second-source confirmation of the covered lives decline: 3.6M (2024) → 2.8M (2026), a 22% drop. Multiple employers in NPR focus groups reported firms 'will no longer cover GLP-1 agonists for weight loss.' The Mercer data shows 66% of employers say GLP-1 had 'significant' impact on prescription drug spending, and 77% of large employers prioritize managing GLP-1 costs. This confirms the access gap is widening despite clinical demand growth.

domains/health/glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-23-icer-glp1-affordable-access-2025.md
 scope: structural
 sourcer: ICER
 supports: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medicaid-glp1-coverage-reversing-through-state-budget-pressure"]
-related: ["glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift"]
+related: ["glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift", "glp1-employer-coverage-declining-despite-utilization-growth-creating-access-gap"]
 ---
 
 # GLP-1 obesity coverage creates acute payer fiscal crisis with employer plans experiencing >10x PMPM cost increases in 2023-2024 and major insurers reporting operating losses driven primarily by GLP-1 expenditures
@@ -38,3 +38,10 @@ Evernorth EncircleRx reports ~$200 million saved since 2024 across 9 million enr
 **Source:** DistilINFO April 2026
 
 Blue Cross Blue Shield Michigan reported $350M increase in GLP-1 drug costs in 2023 alone. Blue Cross Blue Shield Massachusetts reported $400M operating loss in 2024 driven largely by GLP-1 spending. These are major regional Blues plans with broad population coverage, confirming the fiscal unsustainability is affecting diverse payer types, not just large employers.
+
+
+## Supporting Evidence
+
+**Source:** NPR April 22, 2026; Mercer 2026
+
+One employer in the NPR article reported GLP-1 weight-loss spending increasing 50% year over year, corroborating the fiscal unsustainability finding. Mercer reports 59% of the largest employers (5,000+ workers) say GLP-1 costs exceeded expectations, and 66% report 'significant' impact on prescription drug spending. This confirms the cost trajectory is forcing payer responses.

inbox/archive/health/2026-04-22-npr-glp1-coverage-decline-insurance-slipping-2026.md

@@ -7,10 +7,13 @@ date: 2026-04-22
 domain: health
 secondary_domains: []
 format: thread
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-01
 priority: high
 tags: [GLP-1, obesity, employer-coverage, covered-lives, insurance-access, cost-crisis, Wegovy, Zepbound]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content